Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

NCT07569965 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Miltenyi Biomedicine GmbH

Collaborators

[object Object]
[object Object]